The global bronchitis treatment market is anticipated to grow at a considerable CAGR of 4.7% during the forecast period.  Bronchitis is a non-communicable disease, generally caused due to pollution, smoking, bacterial infections, and dust or toxic gases in the environment.  Cigarettes smoking is the prominent cause of bronchitis, and its increasing prevalence is likely to boost the market growth. In 2018, 9.0 million adults, or 3.6% of those ages 18 or older, had chronic bronchitis. According to information provided by the Center for Disease Control and Prevention, in May 2020, more than 16 million Americans are living with a disease caused by smoking, for every person who dies because of smoking, at least 30 people live with a serious smoking-related illness. Moreover, cigarette smoking is responsible for more than 480,000 deaths per year in the US, and if the smoking continues at the current rate among the youth, around 5.6 million Americans younger than 18 years, are expected to die prematurely from smoking-related problems.

In addition, factors such as rising levels of chemical pollutants, gastric reflux, and the risk associated with smoking such as lung, bronchus, and trachea cancer, and growing awareness of COPD in the general population in emerging economies is also a favorable trend in the expansion of the global bronchitis treatment market.  

Impact of COVID-19 Pandemic on Global Bronchitis Treatment Market 

The COVID-19 pandemic had impacted the global bronchitis treatment market to a great extent. The bronchitis treatment market was badly impacted which has led to a reduction in the number of patient visits, which reduced the number of patients opting for bronchitis treatment, thereby impacting the market growth. Additionally, as the COVID-19 pandemic spread to over 213 countries, governments across the globe restricted the exports and imports of goods and services which further affected the demand for bronchitis treatment equipment, which resulted in a huge gap between the supply and demand. 

Segmental Outlook 

The global bronchitis treatment market is segmented based on by drug, distribution channel, and type. Based on drug the market is segmented into antibiotics, anti-inflammatory drugs, bronchodilators, mucolytic. Based on distribution channel, the market is bifurcated into retail pharmacies, online pharmaceutical stores, and hospital pharmacies. The online pharmacies stores is augmented to grow at the fastest rate, owing to growing trend of internet along with rising adoption of smart phones, and various discounts and cash back offers provided by online pharmaceutical stores, has led to support the growth of online pharmaceutical stores for global bronchitis treatment market. Based on typer, the market is sub-divided into acute and chronic 

Global Bronchitis Treatment Market Share by Drug, 2022 (%)

The Bronchodilator Holds the Major Share in the Global Bronchitis Treatment Market 

The bronchodilator segment is anticipated to grow at a significant rate over the forecast period. The bronchodilator is majorly driven by focusing on the development of monoclonal antibody therapy. A monoclonal antibody is mainly used for the treatment of diseases such as a tumor. Moreover, rising in the number of people who are suffering from asthma, COPD is behind the growth of bronchodilator. According to WHO, in 2019, only half of the people who suffered from asthma had access to a bronchodilator and less than one in five had access to a steroid inhaler in public primary healthcare facilities in low-income countries. The increasing prevalence of CPOD and other chronic diseases are likely to increase the demand for bronchitis treatment during the forecasted period. 

Regional Outlooks

The global bronchitis treatment market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East &Africa, and Latin America). North America accounted for the largest share of revenue in 2022 and is expected to maintain its presence over the forecast period. Major factor accelerating the growth of the market include the rising incidence of COPD coupled with significant growth in the geriatric population, along with growing trend of urbanization, industrialization in the countries such as US and Canada, which leads to growing percentage of harmful chemical substances in the air, thus causing problems related with bronchitis, and lungs. 

Global Bronchitis Treatment Market Growth, by Region 2022-2028

The North-America Region Holds the Major Share in the Global Bronchitis Treatment Market 

Geographically, North America dominated the market by accounting highest share in the bronchitis treatment market in 2021. The region is further projected to maintain its dominance during the forecast period. The reason is due to increasing  prevalence of COPD, rise in the geriatric population with an augmented incidence of bronchitis. As per American Lung Association, in 2018, 16.4 million people, or 6.6% of adults, reported a diagnosis of any type of COPD (chronic bronchitis, emphysema, or COPD). Moreover, increasing use of vehicles leads to rise in air pollution, which in turn results in higher number of bronchitis patients in the region. As a result, the demand for bronchitis treatment has increases in the North-America region.  Further, with the compliance of strict regulations, rental firms are increasingly inclined towards expanding their fleet with low emissions loaders, excavators, and other equipment which is necessary for road building, infrastructure development, and for other construction and drilling activities.      

Market Players Outlook

The major companies serving the global bronchitis treatment market are AstraZeneca PLC’, Bayer AG, GSK, Novartis International AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in September 2020, Teva Respiratory completed its digital inhaler portfolio with the launch of AirDuo Digihaler and the ArmonAir Digihaler. Both the inhalers are designed to treat the people with asthma. The AirDuo is used to control symptoms of asthma and prevent symptoms such as wheezing, while ArmonAir is designed for the long term treatment of asthma. Moreover, the digihalers are equipped with bluetooth wireless technology that automatically records inhaler-use data every time the cap is opened or a user inhales.  

The Report Covers

• Market value data analysis of 2022 and forecast to 2028.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global bronchitis treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.